Latest Us Market News

Imricor Medical Systems has taken a significant step toward US market entry by submitting its Advantage-MR EP Recorder/Stimulator system for FDA 510(k) clearance, aiming to enhance MRI-guided cardiac procedures.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Nova Minerals plans to redomicile to the United States following the loss of its foreign private issuer status, while acquiring full ownership of its Estelle Gold and Critical Minerals Project and appointing a US-based CFO.

Aurora Energy Metals updates investors on its strategic option agreement with Eagle Energy Metals, which is set to become the first US-listed uranium explorer with SMR technology following a pending SPAC merger.

Aroa Biosurgery reaffirms strong FY26 guidance, buoyed by favourable US Medicare reimbursement for Symphony and promising trauma study results for Myriad.

Resolution Minerals has taken a significant step towards expanding its footprint in the US capital markets by lodging a registration statement with the SEC and launching an ADR facility, while divesting a non-core Alaskan asset to focus on key US projects.

Xero Limited has outlined a bold AI strategy and detailed the integration of Melio to accelerate its US market growth, supported by new financial disclosures and a clear path to profitability.

Xero Limited reveals new AI product demonstrations and updates on Melio’s integration, reaffirming ambitious US growth and FY28 revenue targets.

Credit Corp Group posted a steady first half with 4% revenue growth and flat net profit, setting the stage for a robust second half driven by increased lending and debt buying investments.

Peak Processing Limited has raised $2.72 million through a discounted share placement to fund growth and operational improvements in its Canadian and US markets. Key directors are backing the raise, signalling confidence in the company’s strategy.

Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.

Adheris Health has expanded its operating cost reduction program, aiming for more than 30% savings by FY27, while refocusing on high-growth pharmaceutical categories and enhancing its AI-powered patient engagement platform.